Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 26, 2015, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $232.50 to $546,600,000.00.

Highlighted Stocks Traded by Insiders:

Washington Trust Bancorp (WASH) - FREE Research Report

Algiere Dennis L, who is SVP Ch Comp Off/Dir Com Affair at Washington Trust Bancorp, sold 244 shares at $37.32 on May 26, 2015. Following this transaction, the SVP Ch Comp Off/Dir Com Affair owned 8,525 shares meaning that the stake was reduced by 2.78% with the 244-share transaction.

The shares most recently traded at $37.11, down $0.21, or 0.57% since the insider transaction. Historical insider transactions for Washington Trust Bancorp go as follows:

  • 4-Week # shares bought: 150
  • 4-Week # shares sold: 500
  • 12-Week # shares bought: 150
  • 12-Week # shares sold: 500
  • 24-Week # shares bought: 150
  • 24-Week # shares sold: 500

The average volume for Washington Trust Bancorp has been 29,900 shares per day over the past 30 days. Washington Trust Bancorp has a market cap of $629.9 million and is part of the financial sector and banking industry. Shares are down 7.44% year-to-date as of the close of trading on Tuesday.

Washington Trust Bancorp, Inc. operates as the holding company for The Washington Trust Company that offers various banking and financial products and services to individuals and businesses. The company operates in two segments, Commercial Banking and Wealth Management Services. The stock currently has a dividend yield of 3.63%. The company has a P/E ratio of 14.9. Currently, there are no analysts who rate Washington Trust Bancorp a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on WASH - FREE

TheStreet Quant Ratings

rates Washington Trust Bancorp as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Washington Trust Bancorp Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biomarin Pharmaceutical (BMRN) - FREE Research Report

Ajer Jeffrey Robert, who is SVP, Chief Commercial Of at Biomarin Pharmaceutical, sold 1,625 shares at $126.55 on May 26, 2015. Following this transaction, the SVP, Chief Commercial Of owned 39,245 shares meaning that the stake was reduced by 3.98% with the 1,625-share transaction.

The shares most recently traded at $129.37, up $2.82, or 2.18% since the insider transaction. Historical insider transactions for Biomarin Pharmaceutical go as follows:

  • 4-Week # shares sold: 11,322
  • 12-Week # shares sold: 16,143
  • 24-Week # shares sold: 30,143

The average volume for Biomarin Pharmaceutical has been 1.5 million shares per day over the past 30 days. Biomarin Pharmaceutical has a market cap of $20.4 billion and is part of the health care sector and drugs industry. Shares are up 40.7% year-to-date as of the close of trading on Tuesday.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently, there are 12 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMRN - FREE

TheStreet Quant Ratings

rates Biomarin Pharmaceutical as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share. Get the full

Biomarin Pharmaceutical Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Advance Auto Parts (AAP) - FREE Research Report

Norona Michael A, who is EVP, CFO & Assistant Secretary at Advance Auto Parts, sold 30,000 shares at $160.00 on May 26, 2015. Following this transaction, the EVP, CFO & Assistant Secretary owned 23,190 shares meaning that the stake was reduced by 56.4% with the 30,000-share transaction.

The shares most recently traded at $157.88, down $2.12, or 1.34% since the insider transaction. Historical insider transactions for Advance Auto Parts go as follows:

  • 4-Week # shares sold: 79,639
  • 12-Week # shares sold: 79,639
  • 24-Week # shares sold: 79,639

The average volume for Advance Auto Parts has been 981,900 shares per day over the past 30 days. Advance Auto Parts has a market cap of $11.7 billion and is part of the services sector and retail industry. Shares are down 0.8% year-to-date as of the close of trading on Tuesday.

Advance Auto Parts, Inc., through its subsidiaries, operates as a specialty retailer of automotive replacement parts, accessories, batteries, and maintenance items. The stock currently has a dividend yield of 0.15%. The company has a P/E ratio of 23.4. Currently, there are 11 analysts who rate Advance Auto Parts a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AAP - FREE

TheStreet Quant Ratings

rates Advance Auto Parts as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, expanding profit margins, good cash flow from operations and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Advance Auto Parts Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.